BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Eosinophilic esophagitis clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for eosinophilic esophagitis: 11 (8 sponsors; 0 newly posted in the last 180 days, 0 stopped in the last 180 days; 0 new-entrant sponsors). Momentum score 13.6, rank 50 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 0, Phase 2 4, Phase 3 3, Phase 4 1, N/A 3.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Regeneron Pharmaceuticals REGN3P2 1, NA 1, P3 100
AstraZeneca AZN1P3 100
Dr. Falk Pharma GmbH1P3 101
Sanofi SNY2NA 1, P4 100
Eupraxia Pharmaceuticals Inc. EPRX1P2 101
Kate Farms Inc1NA 100
Phathom Pharmaceuticals, Inc. PHAT1P2 100
Uniquity One (UNI)1P2 101

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P1/P2Eupraxia Pharmaceuticals Inc. EPRXNCT05608681 A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).Eosinophilic Esophagitisrecruiting117
2026-12 est.P2NS Pharma, Inc.NCT06046222 Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With PolyangiitisEosinophilic Granulomatosis With Polyangiitis; Churg-Strauss Syndromeactive not recruiting45
2026-12 est.P3Dr. Falk Pharma GmbHNCT06596252 Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoEEosinophilic Esophagitisactive not recruiting308

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-06P3GlaxoSmithKlineNCT05263934 Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)Eosinophilic Granulomatosis With Polyangiitiscompleted163
2026-10 est.P2Advagene Biopharma Co. Ltd.NCT07250594 A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic AsthmaEosinophilic Asthmanot yet recruiting126
2026-09-21P3AstraZeneca AZNNCT06750289 Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated Eosinophilic Asthmacompleted130
2026-09-11P2Phathom Pharmaceuticals, Inc. PHATNCT06851559 A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksEosinophilic Esophagitisactive not recruiting95
2026-07-14P3AstraZeneca AZNNCT05583227 Efficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisEosinophilic Esophagitisactive not recruiting368

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "eosinophilic esophagitis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.